LDN-071
/ Ladon Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 21, 2024
LDN-071, the novel amino acid-based PAI-1 inhibitor, significantly reduces the severity of acute and chronic inflammation in colitis models
(ECCO-IBD 2025)
- "However, the LDN-071 reduced the expression of inflammation- and fibrosis-related genes and proteins in vitro human models. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."
Immunology • Inflammation • Inflammatory Bowel Disease • IL1B • IL6 • TNFA
July 19, 2024
THE NOVEL AMINO ACID-BASED PAI-1 INHIBITOR, LDN-071 SIGNIFICANTLY REDUCES THE SEVERITY OF ACUTE AND CHRONIC INFLAMMATION IN COLITIS MODELS
(UEGW 2024)
- "Our results showed that LDN-071, a novel amino acid-based inhibitor of PAI-1, significantly ameliorated the severity of acute and chronic colitis in mice. However, the LDN-071 reduced the expression of inflammation- and fibrosis-related genes and proteins in vitro human models. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."
Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL1B • IL6 • TNFA
December 22, 2023
LDN-071, a novel first-in-class amino acid-based PAI-1 inhibitor, significantly reduces the severity of experimental colitis in mice
(ECCO-IBD 2024)
- "It significantly reduces the severity of experimental colitis in mice. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."
Preclinical • Immunology • Inflammatory Bowel Disease • IL1B • IL6 • TNFA
1 to 3
Of
3
Go to page
1